Acne Vulgaris
Conditions
Interventions
IPL group:IPL,
IPL-PDT group:IPL-PDT
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1) Age 18-40 years old, without cognitive impairment, regardless of gender; 2) The diagnosis and grading of acne patients refer to the Pillsbury grading method, and select mild to moderate acne patients in grades I to III located on the face; 3) After fully explaining the purpose and content of this clinical trial (including subjects' compliance matters, etc.), and on the basis of full understanding, voluntarily sign an informed consent form to participate in the clinical trial.
Exclusion criteria
Exclusion criteria: 1) Known allergies to 5-aminolevulinic acid or monocream; 2) Those who have undergone photodynamic therapy within 12 weeks and those who have applied any other impact studies (such as a 3-month history of Tylenol medication, a 1-month history of antibacterial medication, and a 2-week history of facial topical medication before enrollment); 3) Those who take phototoxic or photosensitive drugs (such as sulfonamides, phenothiazines, etc.) within 8 weeks before enrollment; 4) Patients with facial complications and other diseases that may affect the efficacy evaluation (such as dermatitis, eczema, and other light induced skin diseases); 5) Known to suffer from skin photosensitivity and porphyria; 6) Participate in any drug clinical trial within one month prior to participating in this trial (as a subject) 7) Complicated with serious diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, etc; 8) Scar constitution; 9) Pregnant or lactating women, as well as reproductive age subjects (including males) who refuse to take appropriate contraceptive measures during the study period; 10) Subjects who suffer from severe physical or mental illness and are believed by researchers to have a potential impact on treatment, evaluation, or poor adherence to the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Count of acne lesions; | — |
Countries
China
Contacts
Public ContactXiuli Wang
Shanghai Skin Disease Hospital
Outcome results
None listed